SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to detail the (mechanisms underlying the) actions of the GLP-1
receptor agonists and DPP-4 inhibitors on the cardiovascular, renal and gastrointestinal
systems in patients with Type 2 Diabetes Mellitus.
Phase:
Phase 4
Details
Lead Sponsor:
VU University Medical Center
Collaborator:
EU FP7: SAFEGUARD consortium
Treatments:
Dipeptidyl-Peptidase IV Inhibitors Exenatide Glucagon-Like Peptide 1 Liraglutide Sitagliptin Phosphate